Through Evvy's vaginal microbiome test, consumers can now receive insights on fertility. The vaginal microbiome is often overlooked when it comes to fertility, according to Priyanka Jain, CEO and co-founder of Evvy.
Evvy has launched a new line of prescription products to relieve vaginal discomfort. The products are available on the company's website, with prices ranging from $35 to $59.
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
Women's health advocates overwhelmingly came out in support of the White House's $100 million investment into women's health research. However, some noted shortcomings in where the funding is going.
There are a lack of women at venture capital firms. This makes it difficult for women's health startups focused on stigmatized conditions to get funding when pitching to those who don't always have a good understanding, startups say.
Evvy's $14 million funding round was led by Left Lane Capital and included participation from General Catalyst, LabCorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue and Amboy Street Ventures. In total, Evvy has raised $19 million.
After launching an at-home vaginal microbiome test in 2021, Evvy its expanding its services. After taking a test, consumers can received personalized treatment, which may include prescriptions and one-on-one health coaching.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.